NCT03780907 is a Phase 2 clinical trial of E2007 in Epilepsy, sponsored by Eisai Co., Ltd..

Who is sponsoring NCT03780907?

NCT03780907 is sponsored by Eisai Co., Ltd..

What drugs are being tested in NCT03780907?

Interventions in NCT03780907: E2007, E2007, Placebo.

Is NCT03780907 still recruiting?

NCT03780907 is currently completed. Last updated 19 December 2018.

Last reviewed 2018-12-19 · How we verify

NCT03780907

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety and Pharmacokinetics Study of E2007 to Treat Partial and Generalised Seizures in People With Epilepsy

Completed Phase 2 Last updated 19 December 2018

What this trial tests

Phase 2 trial testing E2007 in Epilepsy in 18 participants. Completed in 6 August 2003.

Timeline

14 February 2003

Primary endpoint
6 August 2003

6 August 2003

Quick facts

Lead sponsor	Eisai Co., Ltd.
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	18
Start date	14 February 2003
Primary completion	6 August 2003
Estimated completion	6 August 2003
Sites	1 location across Germany

Drugs / interventions tested

E2007 — full drug profile →
E2007 — full drug profile →
Placebo

Conditions studied

Epilepsy — all drugs for Epilepsy →

Sponsor

Eisai Co., Ltd. — full company profile →

Who can join

Adults 18 to 65, any sex, with Epilepsy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objectives of this study were to assess the tolerability and safety of E2007 in patients with refractory partial or generalised seizures and to assess the pharmacokinetics of E2007 in epileptic patients receiving at least one concomitant anti-epileptic drug.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Perampanel add-on for drug-resistant focal epilepsy.
Bresnahan R, Hill RA, Wang J. · · 2023 · cited 8× · PMID 37059702 · DOI 10.1002/14651858.cd010961.pub2

Verify or expand the search:

Other trials of E2007

Trials testing the same drug.

NCT03201900 — Study for Verification of Efficacy and Safety for Perampanel Monotherapy in Untreated Participants With Partial Onset Se · Phase 3 · completed

Other recruiting trials for Epilepsy

Currently open trials in the same condition.

NCT07095933 — The Safety and Efficacy Evaluation of Everolimus as an Adjunctive Treatment for Focal Refractory Epilepsy · EARLY_PHASE1 · recruiting
NCT07224191 — Hippocampal Oscillations During Exploration · NA · recruiting
NCT07219407 — A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures · Phase 2 · recruiting
NCT07417280 — LIFUS For Neurological Disorders · NA · recruiting
NCT07490769 — Levetiracetam Three Times Daily in Epilepsy · Phase 3 · recruiting

Other Eisai Co., Ltd. trials

Trials by the same sponsor.

NCT07515014 — A Study of E6742 in Participants With Systemic Lupus Erythematosus · Phase 2 · not yet recruiting
NCT06793709 — A Post-marketing Observational Study of Tasfygo in Participants With Unresectable Biliary Tract Cancer With Fibroblast G · recruiting
NCT06657378 — A Study to Evaluate the Safety of Fycompa Injection in Participants With Partial-Onset Seizures or Primary Generalized T · recruiting
NCT06322667 — A Post Marketing Study in Participants With Early Alzheimer's Disease Treated With Lecanemab · recruiting
NCT05633108 — A Study Based on the French National Health Insurance Database in Participants With Psychotic Disorders · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03780907 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Eisai Co., Ltd.
Last refreshed: 19 December 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03780907.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing